Announcement • Feb 04
T2 Biosystems, Inc. Announces Intent to Complete Winding Down of Operations T2 Biosystems, Inc. announced it will complete winding down operations immediately and will voluntarily liquidate and wind down the Company. This will complete the process that was initiated on February 14, 2025, when the then Board of Directors of the Company authorized the immediate termination of all employees. Announcement • Jul 04
Nasdaq to Delist Common Stock of T2 Biosystems The Nasdaq Stock Market announced that it will delist the common stock of T2 Biosystems, Inc. T2 Biosystems’s stock was suspended on February 12, 2025 and has not traded on Nasdaq since that time. Announcement • Apr 10
T2 Biosystems, Inc. Announces CFO Changes T2 Biosystems, Inc. announced on April 3, 2025, John Sprague notified the Company of his resignation from his position as the Company’s Chief Financial Officer. On April 3, 2025, the Board appointed Craig R. Jalbert, age 63, as a Class I director and the Company’s Chief Executive Officer, President, Corporate Treasurer, and Corporate Secretary, effective as of on April 3, 2025. Mr. Jalbert will serve on the Board until 2027 Annual Meeting of Stockholders and until his successor is duly elected and qualified, or until his earlier death, resignation or removal. Mr. Jalbert will also serve as the Company’s principal executive officer, principal financial officer. Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice in distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases. 
